NS Partners’s Haemonetics HAE Stock Holding History

NS Partners’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-99,541	Closed	-$11.1M	–	72
2021 Q1	$11.1M	Buy	99,541 +558	+0.6%	+$69K	0.64%	57
2020 Q4	$11.8M	Buy	98,983 +1,346	+1%	+$145K	0.69%	56
2020 Q3	$8.52M	Buy	97,637 +19,821	+25%	+$1.73M	0.56%	57
2020 Q2	$6.97M	Buy	+77,816	New	+$7.86M	0.52%	61

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

LCOV

London Company of Virginia Richmond, Virginia $16.2B AUM 17.5% 1-Year Est. Return

LCP

LGT Capital Partners Pfaeffikon, Switzerland $1.97B AUM 15.72% 1-Year Est. Return

NS Partners's HAE Position: Q2 2021 in Review

NS Partners sold out of Haemonetics (HAE) in Q2 2021, closing a stake of 99,541 shares — an estimated $11.1M sold.

NS Partners first reported a position in HAE in Q2 2020 and held it in 4 quarters. The position peaked at $11.8M in Q4 2020. 258 funds tracked by Wall St. Rank hold HAE as of Q2 2021.

NS Partners reported no remaining Haemonetics position as of Q2 2021 after selling out during the quarter.
NS Partners sold 99,541 Haemonetics shares in Q2 2021, an estimated $11.1M.
NS Partners first reported a position in Haemonetics in Q2 2020 and held it in 4 quarters.
NS Partners's Haemonetics position peaked at $11.8M in Q4 2020.
258 funds tracked by Wall St. Rank held Haemonetics as of Q2 2021.

Based on NS Partners's 13F filing for Q2 2021, filed 2 Aug 2021.